CLINICAL STAGE IV HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE IV HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IV HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IV HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo shows promise against tough head and neck cancers
Disease control OngoingThis study tests a combination of an immunotherapy drug (cemiplimab) and two low-dose chemotherapy drugs (paclitaxel and carboplatin) in people whose head and neck cancer has returned or spread. The goal is to see if this mix can shrink tumors better than standard treatments. Abo…
Matched conditions: CLINICAL STAGE IV HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Marcelo Bonomi • Aim: Disease control
Last updated May 01, 2026 15:41 UTC
-
New hope for head and neck cancer: Three-Drug showdown after immunotherapy fails
Disease control OngoingThis study compares three different drug combinations for people with advanced head and neck cancer that has spread or come back after prior treatment, including immunotherapy. About 430 adults will receive either standard chemotherapy plus cetuximab, chemotherapy plus bevacizuma…
Matched conditions: CLINICAL STAGE IV HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC